Patient-Reported Outcomes with Benralizumab in Patients with Severe Eosinophilic Asthma and Severe Chronic Rhinosinusitis with Nasal Polyps

Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) and severe eosinophilic asthma (SEA) are common comorbidities characterised by type 2 inflammation associated increased expression of interleukin 5. Methods: Eight patients SEA CRSwNP attended the Scottish Centre for Respiratory Research as part a clinical trial (EudraCT number 2019-003763-22). Following an initial 4-week run-in period (baseline) when took their usual inhaled intranasal corticosteroid treatment CRSwNP, they all received subcutaneous benralizumab 30 mg q4w 12 weeks. Results: weeks benralizumab, no significant differences were detected in global symptom visual analogue score (VAS), hyposmia VAS, total score, or peak inspiratory flow. In contrast, Asthma Control Questionnaire significantly improved along near-complete depletion peripheral blood eosinophils 99%, while eosinophil-derived neurotoxin fell 72%. Conclusions: Greater improvements patient-reported outcomes related to observed than response benralizumab.